Singapore#s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer

Food and Healthcare Press Releases Monday August 20, 2018 08:00
SINGAPORE--20 Aug--PRNewswire/InfoQuest

Lion TCR Pte. Ltd., a Singapore-based Biotech company receives approval from Health Sciences Authority (HSA), Singapore, for its Phase I/II multicentre clinical study of its product candidate (LioCyx(TM)) for treatment of relapsed liver cancer post-liver transplantation. The first such trial in Singapore and for the region that uses precision T cell receptor (TCR) immune cell therapy to target Hepatitis B virus (HBV)-related liver cancer, which forms at least 80% of liver cancers in Asia. 80% of the 800,000 new liver cancer cases in the world yearly are diagnosed in Asia Pacific, including China, Vietnam, Thailand, Indonesia, South Korea and Singapore. Liver cancer is the world's third most deadly cancer with very limited treatment options and poor treatment outcome. There is currently no effective treatment available for liver cancer relapsed patients post-liver transplantation.

LioCyx(TM) is developed by Lion TCR's scientific founder, Prof. Antonio Bertoletti, a world-renowned HBV-liver cancer clinician scientist. Several Investigator-sponsored trials of LioCyx(TM) in Singapore and China have showed results of good safety profile and encouraging signs of efficacy. "We are very delighted with the approval of Phase I/II clinical trial of our LioCyx(TM), the first engineered TCR-T cell therapy for treatment of liver cancer in Singapore. It is an utmost encouragement on the recognition of innovative therapy for patients in need. Singapore HSA has been very efficient, transparent and professional in reviewing our application for the clinical trial of this innovative immunotherapy", said Dr. Victor Li Lietao, founder and CEO of Lion TCR.

Patients recruitment for the Phase I/II clinical trial will begin with National University Hospital (NUH), Singapore. Lion TCR is in the midst of including more medical centres in Singapore and China into the trial.

About Lion TCR

Lion TCR is a Singapore-based clinical stage biotech company focusing on development of engineered T cell immunotherapy against viral-related cancer and chronic hepatitis B with manufacturing and clinical trial operations in China and Singapore. It is the first company in the world to develop HBV-specific TCR T cell therapy against liver cancer.

Lion TCR's engineered T cell technologies are exclusively licensed from Agency for Science, Technology and Research (A*STAR), Singapore (TCR-T cell therapy developed by Prof. Antonio Bertoletti's lab), and from Technical University of Munich (CAR-T cell therapy developed by Prof. Urlike Protzer's lab).

Lion TCR has recently raised US$ 20 million new investments to advance the clinical trials of LioCyx(TM) in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumours and clearance of chronic hepatitis B.

For more information about Lion TCR, please visit http://www.liontcr.com/or contact info@liontcr.com
For more information about Lion TCR's clinical trials, please contact clinicaltrials@liontcr.com

Latest Press Release

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Ascensia Diabetes Care Highlights the Support That Families Provide for People With Diabetes To Mark World Diabetes Day 2018

Today, Ascensia Diabetes Care, a global leading diabetes care company, launched their campaign for World Diabetes Day 2018 to celebrate the important role of families for people with diabetes. They are publishing 38 online artworks that tell the stories...

Qatar Foundation Ushers in New Era of Healthcare With Official Inauguration of Sidra Medicine

Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation (QF), today officially inaugurated Sidra Medicine - a brand new, world-leading women's and children's hospital in Qatar. The grand opening reflects the country's broader focus and...

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

TIENS Group Launches Global Expansion Into New Retail

Leading healthcare company, TIENS Group, has announced their global expansion into the new retail market with the opening of a new flagship TIENS Experience Store in China. Located in the TIENS International Health Industrial Park, the new store features...

Related Topics